Vertex Pharmaceuticals (VRTX) Operating Leases (2009 - 2026)

Vertex Pharmaceuticals has reported Operating Leases for 18 years, with the latest figure at $2.0 billion in Q2 2026.

• On a quarterly basis, Operating Leases rose 29.47% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 29.47% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 13.18% from the prior year.
• Operating Leases was $2.0 billion for Q2 2026 at Vertex Pharmaceuticals, roughly flat from $2.0 billion in the prior quarter.
• The five-year high for Operating Leases was $2.0 billion in Q1 2026, with the low at $354.4 million in Q3 2023.
• Average Operating Leases over 5 years is $998.2 million, with a median of $507.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slipped 10.84% in 2023, then soared 366.99% in 2024.
• Over 5 years, Operating Leases stood at $428.1 million in 2022, then fell by 10.84% to $381.7 million in 2023, then surged by 327.43% to $1.6 billion in 2024, then increased by 13.18% to $1.8 billion in 2025, then grew by 7.1% to $2.0 billion in 2026.
• The last three Operating Leases figures came in at $2.0 billion (Q2 2026), $2.0 billion (Q1 2026), and $1.8 billion (Q4 2025), per Business Quant data.